得宝松联合自拟鼻炎方治疗过敏性鼻炎150例临床疗效研究  

Treating 150 cases with allergic rhinitis in TCM

作　　者：陈鸿杰[1] 邹增城 李跃[1] 

机构地区：[1]中山大学附属第三医院,广东广州510630

出　　处：《中医临床研究》2017年第9期77-79,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:评价得宝松联合自拟鼻炎方用于过敏性鼻炎(AR)的临床疗效。方法:将2013年1月-2015年12月在我院接受治疗的150例AR患者随机分为A组(50例)、B组(50例)和C组(50例),分别给予得宝松、自拟鼻炎方及联合治疗。比较3组的治疗效果。结果:C组治疗总有效率96.0%,与A组的80.0%和B组的78.0%比较,差异均具有统计学意义(P<0.05),而A、B两组之间无明显差异(P>0.05);C组患者PEF和PEF昼夜变异率改善情况显著好于A组和C组(P<0.05);C组治疗后Ig-E、TNF-α、IL-4及IL-12优于其余两组(P<0.05);3组不良反应总发生率无明显差异(P>0.05)。结论:得宝松联合自拟鼻炎方可有效提高AR的临床疗效,且无明显不良反应。Objective:To evaluate the Diprospan combined with Chinese herbal medicine decoction for allergic rhinitis(AR).Methods:150patients with AR were randomly divided into group A(50cases),group B(50cases)and group C(50cases),were given Diprospan and TCM decoction,respectively.Results:The total efficiency of C group(96.0%),was significantly higher than A group(80.0%)and B group(78.0%)(P<0.05),there was no significant difference between A and B group(P>0.05).The improvement of PEF and PEF in C group was significantly better than that in group A and group C(P<0.05);Ig-E,TNF-,IL-4and IL-12after treatment in group C were better than the other two groups(P<0.05).The improvement of PEF and PEF in C group was significantly better than that in group A and group C(P<0.05);Ig-E,TNF-,IL-4and IL-12after treatment in group C were better than the other two groups(P<0.05).The total incidence of adverse reactions of the3groups had no significant difference(P>0.05).Conclusion:Diprospan plus TCM medicine decoction can effectively improve the clinical efficacy of AR.

关 键 词：过敏性鼻炎 得宝松 自拟鼻炎方 疗效 

分 类 号：R276.1[医药卫生—中医五官科学]